- Recce Pharmaceuticals (RCE) secures trademark registration for RECCE in Vietnam
- It was issued by the Intellectual Property Office of Vietnam
- Vietnam’s pharmaceutical market is expected to reach A$25.2 billion in value by 2026
- Recce aims to combat antibiotic-resistant superbugs, addressing a global health threat
- RCE shares last traded at 69 cents
Recce Pharmaceuticals (RCE) has been granted trademark registration for RECCE by the Intellectual Property Office of Vietnam.
The trademark covers RECCE use across the following classes and specifications: antibiotics, antibiotics for human use, and pharmaceutical preparations.
In 2020, Vietnam’s pharmaceutical market was valued at approximately US$10 billion (A$15.6 billion), doubling in value since 2015.
It is also expected to reach US$16.1 billion (A$25.2 billion) by 2026.
This growth has been accompanied by an alarming rise in antibiotic resistance, making Vietnam one of the global hotspots for this issue.
The extensive use of last-resort antibiotics in large hospitals has fueled bacterial resistance, rendering common treatments ineffective.
With newly submitted patents pending in Vietnam, this trademark registration increases Recce Pharmaceuticals’ intellectual property portfolio.
The RECCE trademark already holds registrations in major pharmaceutical markets worldwide, including the United States, Israel, China, Australia, Japan, Hong Kong, and Europe.
“We are thrilled to receive this newly awarded trademark in Vietnam, further strengthening Recce’s intellectual property portfolio in the Asia-Pacific region,” RCE CEO James Graham said.
RCE shares last traded at 69 cents.